AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.